OV329
Sponsors
Ovid Therapeutics Inc.
Conditions
EpilepsyFocal epilepsy
Phase 2
Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.
Not yet recruitingCTIS2026-527114-23-00
Target: 12Updated: 2026-08-03
A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Potential Antiseizure Activity of Adjunctive OV329 Therapy in Adults with Drug-Resistant Focal Epilepsy
Not yet recruitingCTIS2026-525896-23-00
Target: 6Updated: 2026-08-21